Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notice of the Annual General Meeting

UPM-Kymmene Corporation      Notice to general meeting         31 January 2018 at 12:00 EET Notice of the Annual General Meeting Notice is given to the shareholders of UPM-Kymmene Corporation of the Annual General Meeting to be held on Thursday, 5 April 2018 starting at 14.00 (EET) at Messukeskus, Messuaukio 1, Helsinki, Finland (Kokoustamo entrance). The reception of attendees who have preregistered for the meeting and the distribution of voting tickets will commence at 13.00 (EET). A. Matters on the agenda of the Annual General Meeting 1. Opening of the meeting  2.

Cyxone's cyclotide study into inflammatory bowel disease starts at Medical University of Vienna

In response to interest from drug companies, Cyxone is to review whether cyclotides are effective against inflammatory bowel disease (IBD). The study was planned by the Medical University of Vienna and is now underway.Investigating the effects of cyclotides on IBD has become more relevant following Cyxone's discovery that the company's cyclotide T20K appears to accumulate in the intestine, the organ affected by IBD. Cyxone is following the IBD study with considerable interest. The study is expected to report in March this year. The company will then review the results of the study, and

NCC divests two retail projects in Finland for SEK 540 million

Today, NCC divested two retail projects in Finland: Suurpelto Center in Espoo and Laajasalo Shopping Center in Helsinki, to Niam for an agreed-upon property value of approximately SEK 540 million. "The transaction is a good example of how, over the long term, we develop sustainable projects that promote the creation of an attractive solution for a growing Helsinki Metropolitan Area, as well as for tenants and investors. We are also very pleased that Niam chose to acquire these properties in areas where we at NCC still have the ambition of being an active urban developer",

Read original

Closing completed in connection with acquisition of Totalconnect in Italy

Reference is made to the stock exchange announcement from LINK Mobility Group ASA ("LINK" or the "Company") on 21st of December 2017 regarding the signing of a definitive agreement for the acquisition of Italian mobile messaging business Archynet s.r.l. ("Total Connect") from the seller Claudio Gioiosa. LINK has today completed the acquisition of Total Connect by acquisition of all shares. The acquisition was completed based on an agreed enterprise value of EUR 2.337 million, on a cash-free and debt-free basis. The enterprise value is based on an estimated normalized EBITDA for 2017 of

TMG’S TRUTH ANNOUNCES OLIVER SOUTHGATE AS CHIEF TECHNOLOGY OFFICER

TRUTH, the first global blockchain-enabled media agency, today announces the appointment of Oliver Southgate as Chief Technology Officer. Southgate, who joins from retail technology platform Shopitize, has more than 20 years of experience of working in the publishing, marketing and ad technology sectors. He was previously Head of Data and Technology at Havas Media Group UK, MD at The Social Group and Technology Director at Digitas LBi. TRUTH was launched on November 15th, 2017, to global acclaim and is set to revolutionise the media agency model. A new type of media agency, it

NUMBER OF SHARES AND VOTES IN MEDICOVER

The number of votes in Medicover AB (publ) (“Medicover”) has changed as a result of conversions of in total 13,960 class A shares into class B shares carried out in January following requests from shareholders in accordance with the conversion clause in Medicover’s articles of association. Today, the last trading day of the month, there are in total 133,335,195 shares in Medicover, of which 81,334,201 are class A shares, together carrying 81,334,201 votes, and 52,000,994 are class B shares, together carrying 5,200,099.4 votes. The total number of votes in Medicover is 86,534,300.4.

Invitation to webcast in conjunction with Indutrade’s Year-End Report 2017

Indutrade will publish the Year-End Report 2017 on Tuesday 13 February at 08:00 a.m. CET. A webcast will be held on the same day at 11.00 a.m. CET, CEO Bo Annvik and CFO Jan Öhman will present the results, followed by a Q&A session. The presentation will be in English and webcasted live through www.indutrade.se or: http://event.onlineseminarsolutions.com/r.htm?e=1584728&s=1&k=9E44678D86285A04C6078B6B7BF5B3D6 For phone access, please call: UK: +44 203 008 9810 SE: +46 8 566 426 65 US: +1 855 831 5945 The presentation material will be published on our website after the

Presentation of Aspire Global’s 2017 Year-End report – invitation for the audiocast

On February 15th 2018 Aspire Global will be announcing the interim report for the fourth quarter. On that same day at 10:00 (CET) investors, analysts and journalists are welcome to participate in an audiocast with teleconference where the company CEO, Tsachi Maimon, and CFO, Motti Gil, will be presenting the report, followed by a Q&A-session.The presentation will be held in English and is webcasted live through the following link: https://financialhearings.com/event/10774The meeting, including the Q&A-session, is also available by calling one of the following telephone numbers: Sweden:

Nightingale Health awarded “Health Innovation” of the Year

Nightingale Health’s pioneering blood testing service technology has been recognized as “Health Innovation” of the year by the Health Awards 2018 . The Health Awards & Foresight Forum is an annual event focusing on the future vision of Finnish healthcare. Nightingale will allocate its €5,000 prize money towards a planned science magazine for children, equipping the next generation of budding innovators with a passion for medicine, science and technology. "We believe that our technology will provide better tools for the prevention of chronic diseases

Reminder: Conference invitation from the Migration Studies Delegation (Delmi), Wednesday, 7 February 2018

You are cordially invited to participate in a half-day conference on Responsibility Sharing for Refugees and IDPs at Rosenbad Conference Centre in Stockholm on Wednesday, 7 February 2018.The Migration Studies Delegation (Delmi)  is convening a high-level conference to provide opportunity for decision makers and experts to share knowledge and solicit input on the state and future of global, regional and national responsibility sharing for refugees and internally displaced persons (IDPs). Minister for Migration and Deputy Minister for Justice, Heléne Fritzon, will open

Pihlajalinna Plc publishes Financial Statements Release for January 1–December 31, 2017 on Tuesday, February 13, 2018

Pihlajalinna Plc    Press Release     31 January 2018 at 10.30 a.m. Pihlajalinna Plc publishes Financial Statements Release for January 1–December 31, 2017 on Tuesday, February 13, 2018 Financial Statements Release Pihlajalinna Plc will publish the Financial Statements Release for the period January 1-December 31, 2017 on Tuesday, February 13, 2018 at 8.00 a.m. The release will be available on the company website investors.pihlajalinna.fi. Press and analyst meeting A meeting for analysts and the press, conducted in Finnish, will be held on Tuesday, February 13, 2018 at 10.00

Announces positive interim results from a Phase 1/2 study with LiPlaCis and its DRP in heavily pretreated metastatic breast cancer patients

Hoersholm, Denmark, January 31h, 2018 – Oncology Venture Sweden AB (AktieTorget: OV) announces the second interim report from the Phase 2 part of an ongoing LiPlaCis® Phase 1/2 study in hard to treat metastatic breast cancer patients. Clinical benefit to LiPlaCis – a targeted liposomal formulation of cisplatin – is shown in 7 out of 10 evaluable patients, whereas conventional cisplatin treatment of metastatic breast cancer has reported a response rate of only 10 percent in previously conducted trials. The selection of patients for the Phase 1/2 study is aided by the DRP® companion diagnostic

Invitation to Press and Analyst Meeting – Presentation of Saab Year-End Report for 2017

Saab is pleased to invite to a press and analyst meeting, where CEO Håkan Buskhe and CFO Magnus Örnberg present the Saab Group 2017 year-end result.Date: Friday, 16 February at 10:00 (CET) Address: Grand Hôtel, Blasieholmshamnen 8, Stockholm, Sweden Venue: New York The report is published at 7.30 a.m. (CET) the same day. You are welcome to participate on site at Grand Hôtel, watch the live webcast or dial in to the conference call. It is possible to post questions also over the web and conference call. Live webcast: http://saab-interimreport.creo.se/180216 Conference

Eltel completes sale of Danish rail operations

Eltel has today completed the sale of its rail operations in Denmark to Strukton Rail A/S.The final transaction, comprising the maintenance contract with Sund & Bælt A/S, 26 employees and operational equipment used for delivering the relevant maintenance services, will have a negative EBITA effect estimated to DKK 3.4 million in the fourth quarter of 2017 and a negative cash flow effect of DKK 18 million, expected to occur in the first quarter 2018. In February 2017, Eltel decided that its strategic focus will be on the Group’s core businesses in Power and Communication with the

New communication concept highlights BillerudKorsnäs as change ambassador

Change often begins with a question. This fact forms the basis of BillerudKorsnäs’ new communication concept “What if?” – with the ambition to inspire more to challenge conventional packaging for a sustainable future.BillerudKorsnäs’ mission, to challenge conventional packaging for a sustainable future, is based on the fact that innovative and sustainable packaging solutions have an important role to play in delivering solutions to some of the global challenges that we all face today. Through the communication concept “What If?”, classic product positioning is replaced with open questions

Conversion of shares

According to Husqvarna AB´s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in Husqvarna AB. When such a conversion has occurred, the company is obligated by the Act on Trading in Financial Instruments to disclose any such change. In January 2018, at the request of shareholders, 800 Class A shares were converted to Class B shares. The total number of votes thereafter amounts to 158,895,358.7. The total number of registered shares in the company amounts to 576,343,778 shares

Ziccum achieves proof-of-concept in new antibody study

80% of human immunoglobulin antibodies, used to treat a wide range of diseases, are formulated as liquids, which can mean they are fragile, unstable and costly to transport. New results show that Ziccum AB’s spray drying instrument LaminarPace can produce a stable dry powder form of immunoglobulin antibodies—with confirmed activity. ‘This is an important milestone,’ says Ziccum CEO Göran Conradson.The tests, carried out in ISAB’s labs, dried three samples of liquid Immunoglobulin G (IgG) at room temperature, achieving high yields of powder. 25.5 mg of dry powder IgG was generated from a

Pelican chooses Zeeland Family as its agile marketing partner

The leading self-storage provider Pelican Self Storage and Zeeland Family begin an all-encompassing marketing cooperation. By utilizing agile methods from the get-go, the aim is to transform the clutter-filled spaces in Finland to better use. Pelican Self Storage will hand over the development and execution of its operative marketing and marketing plan to Zeeland Family. The cooperation contains both strategic planning, as well as media and digital solutions. “The self-storage solution provided by Pelican has proven to be an excellent concept, yet one that has stayed relatively

Direct sales create results

In January 2017, a dedicated sales representative was employed to handle the domestic Nordic market. The transition to direct sales in the Nordic region has after a startup period led to a clear increase in sales on the Nordic market, comprising of accessories and several HoloMonitor units. Among the customers are University of Bergen, University of Gothenburg and Lund University. “Through the transition to direct sales, we see that dedicated sales staff lead to increasing sales. We thus look forward to rising revenues, as marketing and sales operations continue to expand both

Diaverum acquires two clinics in Brazil, and enters the largest country in Latin America

Diaverum creates a strong presence from the start through the acquisition of the two clinics in Ameng and Clinese. 900 patients will be treated in the clinics and the number is expected to grow.SAO PAULO/GOTHENBURG, (January 31st, 2018) - Diaverum, one of the leading renal care providers worldwide, announce the acquisition of two dialysis treatment centres in the States of Sao Paulo and Sergipe, respectively. With these two acquisitions Diaverum will treat 900 dialysis patients on the Brazilian market and aims to expand further during 2018. Both Ameneg and Clinese have impressive numbers

Dome Energy AB gives reserve update; Proven reserves value up 130%

Dome Energy AB.  (herein after “Dome” and/or “the Company”) announces a large increase in its Oil and Gas reserves. A third-party engineering company has in a report valued Domes proven reserves at $124mm, which is up from $53mm at the end of 2016, with an addition of high quality probable reserves valued at $16mm. The reserve volumes have increased with 70% during the same period, from 4.5 MBOE to 7.6 MBOE. Paul Mørch, CEO: “We are pleased to see that we have been able to achieve this large increase in reserves and value. A large portion of this value is

NextCell Pharma changes ticker to NXTCL

NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL.Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management hasdecided to change the ticker to NXTCL. The new abbreviation might also be used in general market communicationsand company branding. The new ticker will become effective as per 2018-02-07, the company name and ISIN-code (SE0009723125) willremain the same. This information is the information that NextCell Pharma AB is required to disclose under the EU Market AbuseRegulation.

Financial Statements Release 2017: Excellent finish to the record-strong year 2017

UPM-Kymmene Corporation      Financial Statements Release         31 January 2018 at 09:45 EET Financial Statements Release 2017:Excellent finish to the record-strong year 2017 Q4 2017 highlights · Comparable EBIT increased by 29% to EUR 366 million (283 million in Q4 2016). · Sales prices and delivery growth boosted earnings, outstripping the impact of higher input costs and unfavourable currencies. · Strong operating cash flow at EUR 407 million (405 million). · Net debt decreased to EUR 174 million (1,131 million). · UPM and the Government of Uruguay

The rights issue of Oncology Venture is oversubscribed

Hørsholm, Denmark, January 31st, 2018 – Oncology Venture Sweden AB (”Oncology Venture”) today announces that the company’s rights issue of approximately SEK 44.7 million in order to finance planned clinical trials with existing drug candidates and establish a financial buffer, has been oversubscribed. The rights issue was subscribed to approximately SEK 59.6 million, responding to a subscription rate of approximately 133 percent. Through the rights issue a total of 2.745.143 shares are issued and Oncology Venture are provided approximately SEK 44.7 million before issuing costs. The issuing

There are no items matching the current filter
There are no more items matching the current filter
Back to top